The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-01 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
== Discoidin domain receptors == Discoidin domain receptors form a subgroup of receptor tyrosine kinases. Receptor activation happens when collagen binds into preformed DDR dimers on cell membrane, when collagen is bound, a conformational change probably occurs, which causes cytosolic kinases to rotate to face each other, and their autophosphorylation. The exact way of receptor activation is unknown so far. Unlike other tyrosine-kinase receptors, maximal activation of receptors occurs 18 hours after collagen stimulation. They function as receptors for different collagen types, they recognize many fibrillar collagens and they are capable of binding some nonfibrillar collagens as well. Nevertheless, the native conformation of collagen is a requirement for receptor binding, denatured collagen is not bound. DDRs are expressed widely already during development and level of expression is high in adults as well. DDR1 is a homodimer. Its ectodomain consists of a collagen-binding discoidin domain followed by ~200 residues of unknown structure. It binds fibril-forming collagens and primarily type IV collagen, but also collagen of types I, VI, VIII. It is expressed mainly in epithelial cells and leukocytes and expression rate changes due to cell cycle phase. Functions include: mammary gland development; arterial wound repair; regulation of cell proliferation, cell adhesion and MMP expression; kidney function, differentiation and function of leukocytes. DDR2 structure as above. Binds fibril-forming collagens, collagen of types I, II, III and X.
=== Increase in age === When an individual ages, the outermost layer of skin becomes thin despite the number of cell layers remaining unchanged. The number of cells that contain pigment decreases, and the melanocytes that remain increase in size. This is why aging skin looks thin, pale, and translucent. Large spots may be pigmented when some areas are exposed to sunlight. The various alterations in the skin and underlying connective tissue may decrease its strength and elasticity. Also, the blood vessels in the outer skin become more delicate and can result in bruises and bleeding under the skin's surface. The subcutaneous glands also excrete decreased amounts of oil as you age. Men experience this shortage mostly after reaching the age of 80 years. Women may slowly begin excreting less oil after menopause, making it difficult to keep the skin moist. The subcutaneous fat layer also decreases, reducing the insulation and padding capability of the skin. This can put the individual at risk of an injury and makes maintaining body temperature difficult. The sweat glands also reduce the amount of sweat they produce, making the individual's body harder to cool.
Three "File" editions reprinted selected content originally published between 1993 and 1996 in Edge issues 1–36. Each volume of "File" covered 12 issues. "Edge presents... The Art Of Videogames" (2007)
Just as two German companies brought sulfonylureas to market within the same year, Upjohn discovered Eli Lilly had begun clinical trials for carbutamide, another oral hypoglycemic. Upjohn pushed for large-scale clinical trials from 1955–1957, enrolling over 5,000 patients at multiple sites. Upjohn's formulation was preferred when the Lilly formulation demonstrated evidence of toxicity in parallel trials at the Joslin Clinic. Lilly pulled carbutamide and halted development, leaving the field open for Upjohn to market its new treatment. In 1956, Upjohn filed for approval from the Food and Drug Administration. Jeremy A. Greene found the application's size – 10,580 pages in 23 volumes with 5,786 cases reports – was necessary to "render visible the relatively small improvements provided in less severe forms of diabetes." Indeed, Orinase was marketed by Upjohn not as a cure-all for all diabetics, but specifically as a treatment that was "not an oral insulin" and "did not work in all diabetics". Those were the instructions for marketing given to Upjohn's salespeople. As indicated by the FDA application, Orinase had been demonstrated "not to be effective in severe diabetes, but only in milder cases of the disease." Orinase was one of a new class of drugs (including treatments for hypertension and hypercholesterolemia) aimed at providing marginal benefits over existing treatments for patients who had not previously been a target market for pharmaceuticals.
Sources: en.wikipedia.org
=== Life cycle === The life cycle in sheep is typical of the disease. The female flies lay their eggs on the sheep in damp, protected areas of the body that are soaked with urine and feces, mainly the sheep's breech (buttocks). It takes approximately eight hours to a day for the eggs to hatch, depending on the conditions. Once hatched, the larvae then lacerate the skin with their mouthparts, causing open sores. Once the skin has been breached, the larvae then tunnel through the sores into the host's subcutaneous tissue, causing deep and irritating lesions highly subject to infection. After about the second day, bacterial infection is likely and, if left untreated, causes bacterial bloodstream infections or sepsis. This leads to anorexia and weakness and is generally fatal if untreated.
During the Cold War, the United States and the Soviet Union each invested heavily in propaganda designed to sway both domestic and foreign opinion in the respective country's favor, especially using motion pictures. The quality gap between American and Soviet film gave the Americans a distinct advantage over the Soviet Union; the United States was readily prepared to utilize their cinematic superiority as a way to effectively impact the public opinion in a way the Soviet Union could not. Americans hoped that achievements in cinema would compensate for America's failure to keep up with Soviet development of nuclear weapons and advancements in space technology. The use of film as an effective form of widespread propaganda transformed cinema into another Cold War battlefront alongside the arms race and Space Race. Films from both the United States and Soviet Union can be seen as artifacts of propaganda as well as resistance.
During large-scale protests and demonstrations organized by Generation Z against government corruption in Nepal during September 2025, the flag became a key symbol. Protesters displayed the flag with slogans criticizing the luxurious lifestyles of politicians' children on social media. Posts featuring the flag went viral on Nepalese social media, and its adoption quickly spread among protesters. One Nepalese protester interviewed by The Kathmandu Post remarked that the flag's use in Indonesian protests "surely popularised its use in protests in Nepal". As the government of K. P. Sharma Oli was toppled by the protests, protesters hung the flag at the gates of the Singha Durbar palace as it burned.
Chitosan is produced commercially by deacetylation of chitin, which is the structural element in the exoskeleton of crustaceans (such as crabs and shrimp) and cell walls of fungi. A common method for obtaining chitosan is the deacetylation of chitin using sodium hydroxide in excess as a reagent and water as a solvent. The reaction follows first-order kinetics though it occurs in two steps; the activation energy barrier for the first stage is estimated at 48.8 kJ·mol−1 at 25–120 °C (77–248 °F) and is higher than the barrier to the second stage.
DNA ligase (NAD+) (EC 6.5.1.2, polydeoxyribonucleotide synthase (NAD+), polynucleotide ligase (NAD+), DNA repair enzyme, DNA joinase, polynucleotide synthetase (nicotinamide adenine dinucleotide), deoxyribonucleic-joining enzyme, deoxyribonucleic ligase, deoxyribonucleic repair enzyme, deoxyribonucleic joinase, DNA ligase, deoxyribonucleate ligase, polynucleotide ligase, deoxyribonucleic acid ligase, polynucleotide synthetase, deoxyribonucleic acid joinase, DNA-joining enzyme, polynucleotide ligase (nicotinamide adenine dinucleotide)) is an enzyme with systematic name poly(deoxyribonucleotide):poly(deoxyribonucleotide) ligase (AMP-forming, NMN-forming). This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
Alkaptonuria Congenital disorders of joints Diabetes doubles the risk of having a joint replacement due to osteoarthritis, and people with diabetes have joint replacements at a younger age than those without diabetes. Ehlers–Danlos syndrome Injury to joints or ligaments (such as the ACL) Ligamentous deterioration or instability Marfan syndrome Obesity Joint infection
NAD bound to proteins in the Protein Data Bank NAD Animation (Flash Required) β-Nicotinamide adenine dinucleotide (NAD+, oxidized) and NADH (reduced) Chemical data sheet from Sigma-Aldrich NAD+, NADH and NAD synthesis pathway at the MetaCyc database List of oxidoreductases Archived 30 November 2010 at the Wayback Machine at the SWISS-PROT database NAD+
==== Methodological issues in studies ==== Knowledge about the pharmacokinetics of oral progesterone has been complicated by the use of flawed analytical techniques. When progesterone is taken orally, due to first-pass metabolism, very high levels of its metabolites occur. Most previous studies have used a method known as immunoassay (IA) to measure progesterone levels. However, IA without chromatographic separation (CS) has high cross-reactivity and is unable to differentiate between progesterone and metabolites such as allopregnanolone and pregnanolone. As a result, studies that have assessed the pharmacokinetics of oral progesterone using IA have reported falsely high progesterone levels and inaccurate dependent pharmacokinetic parameters. Comparative studies using reliable and exact methods such as liquid chromatography–mass spectrometry (LC–MS) and IA in conjunction with adequate CS have found that IA without CS overestimates levels of progesterone by 5- to 8-fold. For this reason, the use of reliable assays is mandatory when studying the pharmacokinetics of oral progesterone, and an awareness of these methodological issues is likewise essential for an accurate understanding of the pharmacokinetics of oral progesterone. Conversely, the same issues are not applicable to parenteral routes of progesterone such as vaginal administration and intramuscular injection, because these routes are not subject to a first pass and relatively low levels of progesterone metabolites are formed.
Protein occurs in a wide range of food. On a worldwide basis, plant protein foods contribute over 60% of the per capita supply of protein. In North America, animal-derived foods contribute about 70% of protein sources. Insects are a source of protein in many parts of the world. In parts of Africa, up to 50% of dietary protein derives from insects. It is estimated that more than 2 billion people eat insects daily. Protein powders—such as casein, whey, egg, rice, soy and cricket flour—are processed and manufactured sources of protein. People eating a balanced diet do not need protein supplements. The table below presents food groups as protein sources.
In the night of 26–27 February 1991, some Iraqi forces began leaving Kuwait on the main highway north of Al Jahra in a column of some 1,400 vehicles. A patrolling E-8 Joint STARS aircraft observed the retreating forces and relayed the information to the DDM-8 air operations center in Riyadh, Saudi Arabia. These vehicles and the retreating soldiers were subsequently attacked by two A-10 aircraft, resulting in a 60 kilometres (37 mi) stretch of highway strewn with debris—the Highway of Death. New York Times reporter Maureen Dowd wrote, "With the Iraqi leader facing military defeat, Mr. Bush decided that he would rather gamble on a violent and potentially unpopular ground war than risk the alternative: an imperfect settlement hammered out by the Soviets and Iraqis that world opinion might accept as tolerable." Chuck Horner, Commander of US and allied air operations, has written:
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.